SEC Form 4 · accession 0000880771-16-000187
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO · Director
Period of report
Aug 17, 2016
Accepted (ET)
Aug 18, 2016 · 7:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 17, 2016 | M | 100,000 | $1.08 | A | 588,255 | D | |
| Common Stock | Aug 17, 2016 | S | 501,875 | $10.00 | D | 86,380 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F2 | $1.08 | Aug 17, 2016 | M | 100,000 | D | — | Mar 6, 2019 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1Granted under the Issuer's 2005 Equity Incentive Plan.
- F225% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.